|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.21 USD | +1.74% |
|
+6.66% | +69.19% |
| Mar. 06 | Nektar Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) | RE |
| Mar. 03 | Intellia Therapeutics Presents Longer-Term Clinical Data For Lonvoguran Ziclumeran | CI |
Company Valuation: Intellia Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 8,799 | 2,974 | 2,731 | 1,188 | 1,041 | 1,797 | - | - |
| Change | - | -66.2% | -8.18% | -56.51% | -12.31% | 72.55% | - | - |
| Enterprise Value (EV) 1 | 7,713 | 1,712 | 1,718 | 325.8 | 436.2 | 1,458 | 1,455 | 1,251 |
| Change | - | -77.81% | 0.38% | -81.04% | 33.87% | 234.19% | -0.2% | -14.04% |
| P/E ratio | -31.3x | -5.66x | -5.63x | -2.22x | -2.36x | -4.28x | -7.59x | -20.5x |
| PBR | 8.06x | 2.46x | 2.7x | 1.32x | 1.56x | 4.01x | 4.55x | 4.26x |
| PEG | - | -0.1x | 0.5x | 0.71x | 0.1x | 0.64x | 0.2x | 0.3x |
| Capitalization / Revenue | 266x | 57.1x | 75.3x | 20.5x | 15.4x | 30.2x | 7.49x | 3.03x |
| EV / Revenue | 233x | 32.8x | 47.4x | 5.63x | 6.45x | 24.5x | 6.07x | 2.11x |
| EV / EBITDA | -29.6x | -3.8x | -3.39x | -0.62x | -1.01x | -3.27x | -3.46x | -3.19x |
| EV / EBIT | -28.8x | -3.74x | -3.33x | -0.61x | -0.99x | -3.22x | -3.53x | -3.79x |
| EV / FCF | -32.4x | -4.94x | -4.21x | -0.92x | -1.1x | -4.13x | -5.92x | -50.3x |
| FCF Yield | -3.08% | -20.3% | -23.7% | -109% | -90.8% | -24.2% | -16.9% | -1.99% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3.78 | -6.16 | -5.42 | -5.25 | -3.81 | -3.556 | -2.004 | -0.7425 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 33.05 | 52.12 | 36.28 | 57.88 | 67.67 | 59.55 | 239.8 | 593.8 |
| EBITDA 1 | -261 | -450.6 | -506.3 | -524 | -431.2 | -445.7 | -419.9 | -392.1 |
| EBIT 1 | -267.8 | -458.2 | -515.3 | -534.3 | -441 | -452 | -411.7 | -330.1 |
| Net income 1 | -267.9 | -474.2 | -481.2 | -519 | -412.7 | -436.4 | -400.4 | -332.4 |
| Net Debt 1 | -1,086 | -1,262 | -1,012 | -861.7 | -605.1 | -339.2 | -342.1 | -546.3 |
| Reference price 2 | 118.24 | 34.89 | 30.49 | 11.66 | 8.99 | 15.21 | 15.21 | 15.21 |
| Nbr of stocks (in thousands) | 74,419 | 85,234 | 89,555 | 101,849 | 115,830 | 118,134 | - | - |
| Announcement Date | 2/24/22 | 2/23/23 | 2/22/24 | 2/27/25 | 2/26/26 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.2x | 23.96x | -3.2x | -.--% | 1.77B | |
| 33.11x | 5.76x | 17.86x | 1% | 48.69B | |
| 58.54x | 5.08x | 34.15x | -.--% | 35.92B | |
| -19.19x | 540.19x | -18.36x | -.--% | 31.26B | |
| 34.39x | 8.53x | 21.96x | 0.37% | 29.77B | |
| 21.72x | 2.47x | 10.65x | -.--% | 29.62B | |
| 49.28x | 8.82x | 26.56x | -.--% | 15.1B | |
| 30.41x | 4.94x | 22.48x | -.--% | 14.87B | |
| 23.53x | 2.05x | 8.96x | 1.08% | 14.5B | |
| Average | 25.29x | 66.87x | 13.45x | 0.27% | 24.61B | |
| Weighted average by Cap. | 28.50x | 81.06x | 15.13x | 0.34% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- NTLA Stock
- Valuation Intellia Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
